What's in Luye Pharma Group Ltd.'s pipeline?

Luye Pharma Group Ltd. has 28 drugs in our index: 1 marketed, 0 filed, 7 in Phase 3, 2 in Phase 2, 18 in Phase 1.

Which companies overlap with Luye Pharma Group Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Jiangsu Hansoh Pharmaceutical Co., Ltd., Amsterdam UMC, location VUmc, Astellas Pharma Inc, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/luye-pharma-group-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Luye Pharma Group Ltd. — Portfolio Competitive Intelligence Brief

Luye Pharma Group Ltd. pipeline: 1 marketed, 0 filed, 7 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 7 Phase 3 2 Phase 2 18 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
INVEGA SUSTENNA	INVEGA SUSTENNA	marketed
EU-Prolia	EU-Prolia	phase 3	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)	Bone metabolism / Osteoporosis
Placebo, extended-release microspheres	Placebo, extended-release microspheres	phase 3
LY01011	LY01011	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes
LY03005 extended-release tablet	LY03005 extended-release tablet	phase 3	Dopamine D2 receptor antagonist (antipsychotic)	Dopamine D2 receptor	Psychiatry/Neurology
LY09004	LY09004	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes
LY01005	LY01005	phase 3			Oncology
LY06006	LY06006	phase 3

Therapeutic area mix

Diabetes · 2
Bone metabolism / Osteoporosis · 1
Oncology · 1
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 shared drug classes
Amsterdam UMC, location VUmc · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
AstraZeneca · 1 shared drug class
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class
Beijing Chao Yang Hospital · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Luye Pharma Group Ltd.:

Cite this brief

Drug Landscape (2026). Luye Pharma Group Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/luye-pharma-group-ltd. Accessed 2026-05-15.